Danelle Johnston, MSN, RN, ONN-CG, OCN, of AONN+ Appointed to the Biden Cancer Initiative Advisory Committee

May 2018 Vol 9, No 5

Categories:

In the News
Kristin Siyahian

The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the appointment of its Chief Nursing Officer and Senior Director of Strategic Planning and Initiatives, Danelle Johnston, MSN, RN, ONN-CG, OCN, to the Biden Cancer Initiative Advisory Committee.

The mission of the Biden Cancer Initiative is to develop and drive implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research, and care, and to reduce disparities in cancer outcomes. Vice President Joe Biden and Dr Jill Biden, cochairs of the initiative’s Board of Directors, have assembled a leadership team of experts in the fields of medical research, patient care, information technology, finance, management, patient engagement, patient experience, and public policy. The initiative will work with patients and patient organizations, cancer researchers, cancer centers, research universities, governments, and the private and philanthropic sectors to identify and address the critical issues in cancer prevention, research, and care to drive new actions and collaborations toward ending cancer as we know it.

Through these collaborations, the initiative intends to create a renewed sense of urgency around the need to expedite cancer research, care resources, data sharing, and patient navigation. The goal? To reimagine how the government, academia, nonprofits, and the private sector can better organize their resources and systems to collaborate to take on cancer.

Ms Johnston recently attended a Biden Cancer Initiative Advisory Board meeting. “Participating in a national conversation on improving cancer care is a great honor. We are being asked to reconsider how we address cancer from prevention through survivorship. It’s a huge undertaking, but a very exciting one. I’m delighted to be a part of it.”

Related Articles
End-of-Life Care: Moving Beyond Practical Needs of Patients to Emotional Needs of People. An Interview with Kelly Grosklags, LICSW, BCD, FAAGC
Kristin Siyahian
|
August 2021 Vol 12, No 8
An interview with the creator of the award-winning documentary “Dying Is Not Giving Up.”
Patient Engagement in the Digital Age: The Impact of Digital Therapeutics in Oncology Care
Kristin Siyahian
|
Web Exclusives
Deborah Toppmeyer, MD, and Jacquelyn Lauria, RN, MSN, of Rutgers CINJ, and Bob Gold of GoMo Health talk about the impact of Concierge Care at CINJ. This is their story.
FDA Approves New 400 mg Every-6-Weeks Dosing Regimen of Keytruda for All Indications
Web Exclusives
On April 29, 2020, the FDA accelerated the approval of the oral poly ADP-ribose polymerase (PARP) inhibitor niraparib (Zejula; GlaxoSmithKline) as the first and only drug approved for first-line maintenance therapy of all patients with advanced ovarian cancer—including epithelial ovarian, fallopian tube, or primary peritoneal cancer—who have had a complete or partial response to first-line platinum-based chemotherapy.
Cite this Article

Journal of Oncology Navigation & Survivorship. 2018;9:192.

Last modified: November 15, 2022

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country